蛋白酶抑制劑市場－全球產業規模、佔有率、趨勢、機會和預測，依疾病適應症、最終用途、地區和競爭格局分類，2020-2030年預測

2024年全球蛋白酶抑制劑市場規模為69.2億美元，預計2030年將以4.76%的複合年成長率成長至91.5億美元。蛋白酶抑制劑是一類旨在阻斷蛋白酶活性的治療藥物。蛋白酶是切割某些關鍵蛋白質所必需的酶，這些蛋白質對於特定病毒的複製和某些疾病的進展至關重要。全球蛋白酶抑制劑市場的成長主要得益於病毒感染（包括愛滋病和C型肝炎）的日益流行，以及生物技術的不斷進步，這些進步帶來了更多標靶性化合物。

主要市場促進因素

慢性病和傳染病的日益普及是全球蛋白酶抑制劑市場需求的主要促進因素。全球疾病負擔的不斷加重，尤其是人類免疫缺陷病毒（HIV）感染，迫切需要持續研發並擴大有效治療手段的可近性。

主要市場挑戰

藥物抗藥性的持續出現嚴重阻礙了全球蛋白酶抑制劑市場的擴張。這項挑戰直接降低了現有治療藥物的療效，因為標靶病毒和致病因子會發展出規避藥物作用的機制。

主要市場趨勢

治療應用的多元化是全球蛋白酶抑制劑市場的一大關鍵趨勢，使其應用範圍超越了現有的抗病毒適應症。蛋白酶抑制劑過去主要用於治療愛滋病和丙型肝炎等疾病，如今正被探索和開發用於治療更廣泛的疾病，包括各種癌症、發炎性疾病和神經系統疾病。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球蛋白酶抑制劑市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依疾病指徵（HIV/AIDS、C型肝炎、α1-抗胰蛋白酶缺乏症、遺傳性血管性水腫（HAE）、其他）
  • 依最終用途（醫院和診所、研究實驗室和學術機構、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美蛋白酶抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲蛋白酶抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區蛋白酶抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲蛋白酶抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲蛋白酶抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球蛋白酶抑制劑市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Boehringer Ingelheim International GmbH
• Cytoskeleton, Inc.
• Genentech, Inc.
• Merck & Co., Inc.
• Thermo Fisher Scientific, Inc.
• Kerry Group plc
• Mycorena AB
• Omega Protein Corporation

第16章：策略建議

第17章調查會社について,免責事項

The Global Protease Inhibitors Market, valued at USD 6.92 Billion in 2024, is projected to experience a CAGR of 4.76% to reach USD 9.15 Billion by 2030. Protease inhibitors constitute a class of therapeutic agents designed to obstruct the activity of proteases, enzymes essential for the cleavage of proteins critical to the replication of specific viruses and the progression of certain diseases. The global market for these inhibitors is largely supported by the increasing prevalence of viral infections, including HIV/AIDS and hepatitis C, coupled with ongoing advancements in biotechnology that yield more targeted compounds.

Key Market Drivers

The increasing prevalence of chronic and infectious diseases serves as a fundamental demand-side driver for the global protease inhibitors market. The escalating global burden of conditions, particularly human immunodeficiency virus HIV infection, necessitates continuous development and broader access to effective therapeutic interventions. Protease inhibitors remain crucial in HIV management.

Key Market Challenges

The persistent emergence of drug resistance represents a considerable impediment to the expansion of the Global Protease Inhibitors Market. This challenge directly diminishes the efficacy of current therapeutic agents, as target viruses and disease-causing agents develop mechanisms to circumvent drug action. Such evolution reduces the effective lifespan of existing protease inhibitor treatments and continuously drives the need for costly and prolonged research into novel compounds with new mechanisms of action.

Key Market Trends

The diversification of therapeutic applications represents a pivotal trend for the Global Protease Inhibitors Market, expanding its reach beyond established antiviral indications. Historically central to managing conditions like HIV and Hepatitis C, protease inhibitors are increasingly being explored and developed for a broader spectrum of diseases, including various forms of cancer, inflammatory disorders, and neurological conditions. This strategic broadening of focus is driven by a deeper mechanistic understanding of protease involvement in diverse pathological processes, leading to the identification of novel targets suitable for inhibition.

Key Market Players

• Boehringer Ingelheim International GmbH
• Cytoskeleton, Inc.
• Genentech, Inc.
• Merck & Co., Inc.
• Thermo Fisher Scientific, Inc.
• Kerry Group plc
• Mycorena AB
• Omega Protein Corporation

Report Scope:

In this report, the Global Protease Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protease Inhibitors Market, By Disease indication:

• HIV/AIDS
• Hepatitis C
• Alpha-1 Antitrypsin Deficiency
• Hereditary Angioedema (HAE)
• Others

Protease Inhibitors Market, By End-Use:

• Hospitals & Clinics
• Research Laboratories and Academic Institutes
• Others

Protease Inhibitors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Protease Inhibitors Market.

Available Customizations:

Global Protease Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protease Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease indication (HIV/AIDS, Hepatitis C, Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema (HAE), Others)
  • 5.2.2. By End-Use (Hospitals & Clinics, Research Laboratories and Academic Institutes, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Protease Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease indication
  • 6.2.2. By End-Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Protease Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease indication
      • 6.3.1.2.2. By End-Use
  • 6.3.2. Canada Protease Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease indication
      • 6.3.2.2.2. By End-Use
  • 6.3.3. Mexico Protease Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease indication
      • 6.3.3.2.2. By End-Use

7. Europe Protease Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease indication
  • 7.2.2. By End-Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Protease Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease indication
      • 7.3.1.2.2. By End-Use
  • 7.3.2. France Protease Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease indication
      • 7.3.2.2.2. By End-Use
  • 7.3.3. United Kingdom Protease Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease indication
      • 7.3.3.2.2. By End-Use
  • 7.3.4. Italy Protease Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease indication
      • 7.3.4.2.2. By End-Use
  • 7.3.5. Spain Protease Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease indication
      • 7.3.5.2.2. By End-Use

8. Asia Pacific Protease Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease indication
  • 8.2.2. By End-Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Protease Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease indication
      • 8.3.1.2.2. By End-Use
  • 8.3.2. India Protease Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease indication
      • 8.3.2.2.2. By End-Use
  • 8.3.3. Japan Protease Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease indication
      • 8.3.3.2.2. By End-Use
  • 8.3.4. South Korea Protease Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease indication
      • 8.3.4.2.2. By End-Use
  • 8.3.5. Australia Protease Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease indication
      • 8.3.5.2.2. By End-Use

9. Middle East & Africa Protease Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease indication
  • 9.2.2. By End-Use
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Protease Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease indication
      • 9.3.1.2.2. By End-Use
  • 9.3.2. UAE Protease Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease indication
      • 9.3.2.2.2. By End-Use
  • 9.3.3. South Africa Protease Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease indication
      • 9.3.3.2.2. By End-Use

10. South America Protease Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease indication
  • 10.2.2. By End-Use
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Protease Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease indication
      • 10.3.1.2.2. By End-Use
  • 10.3.2. Colombia Protease Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease indication
      • 10.3.2.2.2. By End-Use
  • 10.3.3. Argentina Protease Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease indication
      • 10.3.3.2.2. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Protease Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boehringer Ingelheim International GmbH
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Cytoskeleton, Inc.
• 15.3. Genentech, Inc.
• 15.4. Merck & Co., Inc.
• 15.5. Thermo Fisher Scientific, Inc.
• 15.6. Kerry Group plc
• 15.7. Mycorena AB
• 15.8. Omega Protein Corporation

16. Strategic Recommendations

17. About Us & Disclaimer